Alzheimer's drug no cash cow
by Max Nisen The U.S. Food and Drug Administration's approval last week of Biogen Inc.'s Alzheimer's treatment aducanumab was a mistake based on weak evidence. The question now is…
More from Mountaineer Country
Connect Bridgeport Sports
Bridgeport Pounds Preston to Clinch Another Winning Football Season
Mountaineer Country
•
4h ago
Fairmont State Falcons
Women's Swimming Battles Shippensburg and California (Pa.)
Mountaineer Country
•
4h ago
Dominion Post | Morgantown
Heroes make note: No cape necessary for Marion CASA 5K Run and 2K Walk
Mountaineer Country
•
8h ago
Logan Banner
Benson vows to make WVU 'model for the American research university'
Mountaineer Country
•
8h ago
Dominion Post | Morgantown
Spark! event provides first-class aviation education
Mountaineer Country
•
8h ago